Gut health boost could slow kidney disease, new trial hopes

NCT ID NCT07182942

Recruiting now Disease control Sponsor: Chujin Cao Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a drug called Xiqing, which absorbs waste in the gut, works better when combined with probiotics in people with chronic kidney disease (CKD). The trial will enroll 120 adults with moderate to advanced CKD who are not on dialysis. Researchers will track kidney function and heart health to see if the combination helps slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Xiqing (a coated aldehyde oxystarch capsule that absorbs waste) and probiotics (Lactobacillus casei Zhang)
What this could lead to: If successful, this could show that combining Xiqing with probiotics better slows kidney disease progression and reduces complications.
What could go wrong: This is a small, early-phase trial with 120 participants, so results may not apply to all CKD patients. Risks include side effects from the drugs or no added benefit from probiotics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD DRUG EFFECT

Contacts and locations

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.